Clinical trial · Interventional
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
Evaluation of the Trustworthiness of the Application of Artificial Intelligence and Decision Support Systems for the Creation of Tumor Conference Protocols
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to compare the recommendations of the artificial intelligence clinical decision support system 'ADBoard', with the recommendations of physicians by tumor conferences in patients with hepatobiliary tumors. The main questions it aims to answer are: Can ADBoard achieve a high level of similar recommendations as physicians' tumor conferences? Can ADBoard consider a more complete set of patient-related data than in physicians' tumor conferences? Can ADBoard reduce the time between the first time the patient is discussed at the tumor conference and the start of the recommended treatment plan? Participants will have their hepatobiliary tumor treatments determined by either tumor conference with ADBoard, or tumor conference without ADBoard.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma, Perihilar | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.85 |
| Fibrolamellar Hepatocellular Carcinoma | Fibrolamellar Carcinoma | ALIAS | 0.90 |
| Gallbladder Carcinoma | Gallbladder Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Intrahepatic Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Metastasis to Liver | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ADBoard | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Participants' cases discussed in tumor conference without ADBoard
- description
- Participants' cases are discussed in tumor conference without the use of ADBoard, according to conventional practice.
- type
- EXPERIMENTAL
- label
- Participants' cases discussed in tumor conference with ADBoard
- description
- Participants' cases will be evaluated by ADBoard directly before they are discussed in the tumor conference.
- interventionNames
- Other: ADBoard
Primary outcomes (2)
- measure
- Concordance (yes/no) of interdisciplinary tumor conference treatment recommendation with ADBoard-supported recommendation
- timeFrame
- Through study completion, average of 30 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Valid informed consent * Patient information available in the hospital information system or Health Data Platform (HDP) * Enrollment in the hepatobiliary tumor conference * Diagnosis of any of the following entities: Colorectal liver metastasis, Gallbladder carcinoma, Hepatocellular carcinoma (HCC), mixed cell carcinoma, or fibrolamellar carcinoma, Perihilar cholangiocarcinoma (Klatskin tumors), Intrahepatic cholangiocarcinoma (iCC) Exclusion Criteria: * Patient does not consent / incapable of giving consent * Missing findings in the hospital information system * Patient is seeking for a second opinion and is not being treated at the study institution
References
Publications (1)
- DERIVEDNg SST, Oehring R, Ramasetti N, Roller R, Thomas P, Chen Y, Moosburner S, Winter A, Maurer MM, Auer TA, Kamali C, Pratschke J, Benzing C, Krenzien F. Concordance of a decision algorithm and multidisciplinary team meetings for patients with liver cancer-a study protocol for a randomized controlled trial. Trials. 2023 Sep 9;24(1):577. doi: 10.1186/s13063-023-07610-8. PMID 37684688